• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cells . NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19

tetano

Editor, Senior Moderator
Cells


. 2021 Nov 15;10(11):3182.
doi: 10.3390/cells10113182.
NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19


Laura Bergantini[SUP] 1 [/SUP], Miriana d'Alessandro[SUP] 1 [/SUP], Paolo Cameli[SUP] 1 [/SUP], Dalila Cavallaro[SUP] 1 [/SUP], Sara Gangi[SUP] 1 [/SUP], Behar Cekorja[SUP] 1 [/SUP], Piersante Sestini[SUP] 1 [/SUP], Elena Bargagli[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome caused by coronavirus 2 emerged in Wuhan (China) in December 2019 and has severely challenged the human population. NK and T cells are involved in the progression of COVID-19 infection through the ability of NK cells to modulate T-cell responses, and by the stimulation of cytokine release. No detailed investigation of the NK cell landscape in clinical SARS-CoV-2 infection has yet been reported. A total of 35 COVID-19 hospitalised patients were stratified for clinical severity and 17 healthy subjects were enrolled. NK cell subsets and T cell subsets were analysed with flow cytometry. Serum cytokines were detected with a bead-based multiplex assay. Fewer CD56[SUP]dim[/SUP]CD16[SUP]bright[/SUP]NKG2A[SUP]+[/SUP]NK cells and a parallel increase in the CD56[SUP]+[/SUP]CD69[SUP]+[/SUP]NK, CD56[SUP]+[/SUP]PD-1[SUP]+[/SUP]NK, CD56[SUP]+[/SUP]NKp44[SUP]+[/SUP]NK subset were reported in COVID-19 than HC. A significantly higher adaptive/memory-like NK cell frequency in patients with severe disease than in those with mild and moderate phenotypes were reported. Moreover, adaptive/memory-like NK cell frequencies were significantly higher in patients who died than in survivors. Severe COVID-19 patients showed higher serum concentrations of IL-6 than mild and control groups. Direct correlation emerged for IL-6 and adaptive/memory-like NK. All these findings provide new insights into the immune response of patients with COVID-19. In particular, they demonstrate activation of NK through overexpression of CD69 and CD25 and show that PD-1 inhibitory signalling maintains an exhausted phenotype in NK cells. These results suggest that adaptive/memory-like NK cells could be the basis of promising targeted therapy for future viral infections.

Keywords: NK cells; T cells; cytomegalovirus; immunology; lung transplant.
 
Back
Top Bottom